Matthew Johnson News
-
The Reserve Bank of Australia said the country’s currency is held by as many as 34 central banks from Reykjavik to Santiago, and models suggested the Aussie dollar was as much as 15 percent overvalued, documents showed.
-
Johnson & Johnson is set to face its first trial over its vaginal mesh implant in a case brought by a South Dakota woman who blames the product for constant pain and 18 subsequent operations.
-
Johnson & Johnson’s Ethicon unit told a federal judge in West Virginia it intends to stop selling four vaginal mesh implants after being sued by more than 600 women who say the products caused internal injuries.
-
Johnson & Johnson, the biggest health-care products maker, continued to sell a vaginal mesh implant for nine months after U.S. regulators told the company to stop marketing the device, according to court records.
-
Johnson & Johnson sold a vaginal mesh implant for three years before U.S. regulators approved the device, now the subject of more than 550 lawsuits by women who claim it injured them.
-
The Australian bond market may grow 44 percent to about A$740 billion ($785 billion) by June 2015, led by increases in debt sales from regional governments and corporate issuers, UBS AG said.
-
U.S. regulators should be able to block medical devices based on past products with safety issues, said House Democrats, citing injuries from transvaginal implants like those made by Johnson & Johnson and C.R. Bard Inc.
-
Johnson & Johnson, the world’s second-biggest health-care products maker, is battling lawsuits over a vaginal implant based on a similar device pulled from the market more than a decade ago for safety reasons.
-
HSBC Holdings Plc’s proposed $62.5 million settlement with investors in an Irish fund that lost their money in Bernard Madoff’s Ponzi scheme was rejected by a U.S. judge.
-
Johnson & Johnson and C.R. Bard Inc. must study rates of organ damage and complications linked to vaginal mesh implants, U.S. regulators said, responding to patient advocates who say the devices have harmed women.
|
|
Most Popular on Bloomberg
|
| |
Rate this Page